20th week of 2016 patent applcation highlights part 10 |
Patent application number | Title | Published |
20160136265 | PHARMACEUTICAL COMPOSITION FOR VIRAL IMMUNOTHERAPY AND USES THEREOF - The present disclosure relates to a method of overcoming host immune tolerance in a subject having chronic hepatitis B virus (HBV) infection, comprising administering to the subject an immunomodulatory agent and a recombinant HBV vaccine, such that the immune tolerance of the chronic HBV infection in the subject is overcome. Moreover, the present disclosure relates to a method of treating chronic HBV infection in a subject in need thereof, comprising administering to the subject a first anti-viral agent, an immunomodulatory agent and a recombinant hepatitis B vaccine, such that the HBV infection in the subject is treated. | 2016-05-19 |
20160136266 | Vaccine system for vaccine adjuvant - The present invention provides adjuvant compositions that have improved stability, increased potency and which provide an enhanced T | 2016-05-19 |
20160136267 | SPHINGOGLYCOLIPID ANALOGUES - The invention relates to sphingoglycolipid analogues which are useful in treating or preventing diseases and conditions such as those relating to infection, atopic disorders, autoimmune diseases or cancer. | 2016-05-19 |
20160136268 | MAMMALIAN MILK OSTEOPONTIN FOR ENHANCING IMMUNE RESPONSIVENESS - The disclosed invention provides mammalian milk osteopontin and/or an active truncation or active peptide thereof for improving immune responsiveness to an infectious disease in a mammal, for example a human subject, as well as enhancing the efficacy of vaccination for the prophylactic or therapeutic treatment of an infectious disease in mammals, such as humans. The invention further provides a vaccine system, for use in the prophylactic or therapeutic treatment of an infectious disease in a mammal, comprising a vaccine and a mammalian milk osteopontin and/or an active truncation or active peptide thereof for oral administration to a mammal, as well as methods of enhancing immune resistance to an infectious disease in a mammal by administration of a vaccine and a mammalian milk osteopontin and/or an active truncation thereof. | 2016-05-19 |
20160136269 | Composition and Method for Treating Cancer - Pharmaceutical compositions useful as vaccines are described containing a purified surface or excreted protein qualitatively or quantitatively associated with a type of cancer, at least one interleukin (IL), and at least one colony stimulating factor (CSF), where the purified surface or excreted protein is provided in an amount sufficient to induce an immune response in an individual administered the composition. Such compositions can be used in methods for treating individuals having cancer, and for inducing an immunotherapeutic response in the same. | 2016-05-19 |
20160136270 | Ablative immunotherapy - The invention disclosed herein relates generally to immunotherapy and, more specifically, to the use of immunotherapy for treating tumors and pathogen infected tissues by first priming patients with allogeneic cells designed to be rejected by a Th1 mediated mechanism, then inducing necrosis or apoptosis in a tumor or pathogen infected lesion by methods such as cryotherapy, irreversible electroporation, chemotherapy, radiation therapy, ultrasound therapy, ethanol chemoablation, microwave thermal ablation, radiofrequency energy or a combination thereof applied against at least a portion of the tumor or pathogen infected tissue, and then delivering one or more doses of allogeneic cells (e.g., Th1 cells) within or proximate to the tumor or pathogen-infected tissue in the primed patient. The present invention provides an immunotherapeutic strategy to develop de-novo systemic (adaptive) immunity to a tumor or pathogen. | 2016-05-19 |
20160136271 | Disaccharide Synthetic Lipid Compounds and Uses Thereof - Essentially pure compounds of the formulas (I) to (XX) are provided. Compositions and methods for enhancing or stimulating an immune response are also provided. The compounds, provided are advantageous in that the compounds are essentially pure and free from contaminants encountered when such compounds are purified from natural sources. | 2016-05-19 |
20160136272 | METHODS FOR RESTORING CORTICOSTEROID SENSITIVITY - The present invention relates to use of therapeutic agents that specifically bind and inhibit TLR3 signalling in order to sensitize patients to treatment with corticosteroids, notably for the treatment and prevention of inflammatory and autoimmune disorders. | 2016-05-19 |
20160136273 | COMPOSITIONS INCLUDING TRICIRIBINE AND TRASTUZUMAB AND METHODS OF USE THEREOF - This application relates to combination therapies including triciribine and related compounds and trastuzumab or a salt thereof and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation. | 2016-05-19 |
20160136274 | MEDICINAL COMPOSITION FOR PROMOTING SYNTHESIS OF PROTOPORPHYRIN IX - The object of the present invention is to elucidate the resistance mechanism in infections that show resistance to ALA-PDT that uses a single ALA, and to provide a novel treatment method against these infections. The present invention provides a pharmaceutical composition for promoting protoporphyrin IX production in ALA-PDT for treating infection, characterized in that it comprises a substance that promotes the conversion from coproporphyrinogen III to protoporphyrin IX. | 2016-05-19 |
20160136275 | OPHTHALMIC COMPOSITION - An ophthalmic composition comprising geranylgeranylacetone and a phosphate buffering agent has an advantage that the loss of the geranylgeranylacetone content during long-term storage is very little. This is because of reduced adsorption of geranylgeranylacetone to a wall of an ophthalmic container. The ophthalmic composition comprising geranylgeranylacetone and a phosphate buffering agent also has an advantage that adsorption of geranylgeranylacetone to a contact lens is little. Further, the ophthalmic composition comprising geranylgeranylacetone and a phosphate buffering agent hardly becomes white turbid even when stored at low temperature. | 2016-05-19 |
20160136276 | DESENSITIZING DRUG PRODUCT - Desensitizing drug products, methods of making desensitizing drug products, and methods of using desensitizing drug products including delivery of desensitizing drug products. In one embodiment, the desensitizing drug products are male genital desensitizers that comprise one or anesthetic agents and one or more melting point depressing agents. | 2016-05-19 |
20160136277 | Ketoprofen-Containing Aqueous Adhesive Skin Patch - Provided is a water-based patch that contains ketoprofen as an active ingredient, provides high transdermal absorbability of the ketoprofen, and has high safety and high storage stability. The water-based patch contains the ketoprofen, an amine, and polyethylene glycol. In the water-based patch, the added amount of the ketoprofen in a paste is 0.1 to 5% by weight, the added amount of the amine in the paste is 0.5 to 10% by weight, and the added amount of the polyethylene glycol in the paste is 5 to 30% by weight. Particularly, in the water-based patch, diisopropanolamine is used as the amine. | 2016-05-19 |
20160136278 | EXTERNAL-USE COMPOSITION PRODUCING FOAMED STATE UPON USE - A means for increasing the amount of an effective component retained in a composition for a pump foamer is provided. The present invention provides a composition for external use containing: 1) an N-alkyl-2-pyrrolidone and/or a diester carbonate; and 2) a surfactant; which composition is in a foam state upon use. | 2016-05-19 |
20160136279 | PHARMACEUTICAL COMPOSITIONS HAVING IMPROVED STORAGE STABILITY - The present invention relates to a pharmaceutical composition that provides long-term stability of a hydrolytically labile antipsychotic agent | 2016-05-19 |
20160136280 | STABLE INTRAVENOUS FORMULATION | 2016-05-19 |
20160136281 | DELIVERY OF IBUPROFEN AND OTHER COMPOUNDS - The present invention generally relates to the transdermal delivery of various compositions. In some aspects, the transdermal delivery may be facilitated by the use of a hostile biophysical environment. One set of embodiments provides a composition for topical delivery comprising ibuprofen and/or an ibuprofen salt, a nitric oxide donor, and optionally, a hostile biophysical environment. In some cases, the composition may be stabilized using a stabilization polymer such as xanthan gum, KELTROL® BT and/or KELTROL® RD; propylene glycol; and a polysorbate surfactant such as Polysorbate 20, which unexpectedly provides temperature stability to the composition, e.g., at elevated temperatures such as at least 40° C. (at least about 104° F.), as compared to compositions lacking one or more of these. | 2016-05-19 |
20160136282 | NOVEL FORMULATION OF CILOSTAZOL, A QUINOLINONE-DERIVATIVE USED FOR ALLEVIATING THE SYMPTOM OF INTERMITTENT CLAUDICATION IN PATIENTS WITH PERIPHERAL VASCULAR DISEASE - A pharmaceutical composition in solid form containing particulate cilostazol or a salt thereof, a cellulose, a diluent, and a lubricant. The pharmaceutical composition features an in vivo plasma profile for cilostazol of C | 2016-05-19 |
20160136283 | SOLUTION FOR SPRAY DRYING COMPRISING HYPROMELLOSE ACETATE SUCCINATE AND METHOD FOR PRODUCING SOLID DISPERSION - There are provided a solution for spray drying having a high transmittance and markedly reduced generation of undissolved matter; and a method for producing a solid dispersion by using the solution for spray drying so that clogging with the undissolved matter is reduced and dissolution is improved. More specifically, there is provided a solution for spray drying comprising hypromellose acetate succinate (HPMCAS) having a hydroxypropoxy molar substitution of 0.40 or more, a solvent, and a drug. There is also provided a method for producing a solid dispersion comprising the step of removing the solvent from the spray drying solution. | 2016-05-19 |
20160136284 | GLIOMA TREATMENT - A method of treating a glioma is disclosed. The method includes administering to a patient in need thereof a composition that includes a chemotherapy agent and artificial cerebrospinal fluid via convection enhanced delivery. | 2016-05-19 |
20160136285 | AN ISOLATED IMMUNOGENIC BACTERIAL ANTIGEN AND ITS USE IN THE PREVENTION AND TREATMENT OF INFECTIONS CAUSED BY GRAM-NEGATIVE BACTERIA - The subject of the present invention is an isolated antigen being an immunogenic form of the common enterobacterial antigen (ECA) of Gram-negative bacteria of the family Enterobacteriaceae: ECA combined with lipopolysaccharide (ECA | 2016-05-19 |
20160136286 | DRUG DELIVERY COMPOSITION - There is provided a non-water soluble drug delivery composition comprising a conjugate and a polymer matrix wherein exposure of the composition to electromagnetic radiation at a suitable pre-determined wavelength and intensity induces release of the active ingredient from the composition. The conjugate is attached to the polymer matrix through non-covalent interactions. There is also provided a drug delivery apparatus formed from the drug delivery composition. | 2016-05-19 |
20160136287 | CONJUGATED VACCINE - The present invention provides a composition for provoking an immune response in a patient to an autoantigen target, the composition comprising the target conjugated a carrier polypeptide. | 2016-05-19 |
20160136288 | Immunogenic composition in emulsion form comprising two dispersed phases, one comprising an antigen and the other comprising an immunostimulating agent - The application relates to an immunogenic composition comprising a continuous aqueous phase and at least two dispersed phases 1 and 2 as droplets, wherein the dispersed phase 1 comprises a surfactant 1 bearing an antigen and the dispersed phase 2 comprises an immunostimulating agent 2, to its preparation method and its uses, notably for producing antibodies, as a drug, as a vaccine or in an immunization method. | 2016-05-19 |
20160136289 | PHOTOACTIVATABLE LIPID-BASED NANOPARTICLES AS VEHICLES FOR DUAL AGENT DELIVERY - Embodiments of photoactivatable, lipid-based nanoparticles are disclosed, as well as methods of making and using the nanoparticles. Pharmaceutical compositions including the nanoparticles also are disclosed. The lipid-based nanoparticles include a vesicle wall surrounding a cavity, wherein the vesicle wall includes (i) a lipid bilayer comprising 1,2-bis(tricosa-10,12-diynoyl)-sn-glycero-3-phosphocholine (DC | 2016-05-19 |
20160136290 | Phospholipid Ether Analogs as Cancer-Targeting Drug Vehicles - The present invention is directed to therapeutic compounds capable of targeting cancer cells and cancer stem cells. The present invention is further directed to compositions comprising these therapeutic compounds and methods of treating cancer comprising administering these therapeutic compounds. | 2016-05-19 |
20160136291 | POLYMERS FOR DELIVERY OF FACTOR VIII AND/OR FACTOR IX - In some aspects, a composition comprising a pH-sensitive crosslinked copolymer of methacrylic acid and poly(ethylene glycol) monomethyl ether methacrylate and a therapeutic protein is provided. In some embodiments, the therapeutic protein is a high molecular weight protein such as factor VIII or factor IX. In some embodiments, the composition is orally administered to a patient to treat a disease or disorder such as, e.g., hemophilia. | 2016-05-19 |
20160136292 | METAP-2 INHIBITOR POLYMERSOMES FOR THERAPEUTIC ADMINISTRATION - Described herein are MetAP-2 inhibitors and compositions and formulations thereof, and more particularly compositions and formulations of MetAP-2 inhibitors wherein the MetAP-2 inhibitor is associated with a block copolymer comprising a hydrophilic polymer moiety and a hydrophobic polymer moiety. The present invention also relates to compositions and formulations comprising MetAP-2 inhibitors for oral administration or administration via routes such as topical or ocular administration. The present invention also provides methods to treat conditions associated with or related to the over-expression or over-activity of MetAP-2 by administering the compositions and formulations comprising MetAP-2 inhibitors as disclosed herein. | 2016-05-19 |
20160136293 | STRUCTURE, MANUFACTURING AND USES OF HUMAN-DERIVED CELL-PERMEABLE PEPTIDES CONJUGATED WITH SPECIFIC BIOLOGICALLY ACTIVE CARGO PEPTIDES - Embodiments disclosed herein provide compositions for conjugates, including fusion proteins, and methods of using them to treat a variety of conditions. In some embodiments, the conjugates and/or fusion proteins incorporate a 60-amino acid human homeodomain (e.g., peptides derived from human HOX genes), to translocate functional and regulatory peptides and proteins or other biologically active molecules such as nucleic acids, which are not naturally associated with the human homeodomain, across cell and nuclear membranes to intended sites of action without provoking an unwanted immune response that may reduce exposure to the conjugate and/or result in a clinical adverse event. In further embodiments, disclosed conjugates and fusion proteins can pass through the blood-brain barrier to allow entry into the CNS. In various embodiments, the disclosed compositions are suitable for delivery into a cell (i) the expression product of a gene of interest and/or (ii) novel peptides or polynucleotides to regulate gene function. | 2016-05-19 |
20160136294 | BIFUNCTIONAL PROTEIN ANCHORS - The disclosure relates to the areas of immunology and vaccine delivery. More specifically, it relates to a bacterial vaccine delivery technology with built-in immunostimulatory properties which allow the immobilization of any antigen of interest, without prior antigen modification. Provided is an antigen-loaded immunogenic carrier complex comprising at least one bifunctional polypeptide attached to an immunogenic carrier, the bifunctional polypeptide comprising a peptidoglycan binding domain (PBD) through which the polypeptide is attached to the carrier, fused to an antigen binding domain (ABD) to which at least one antigen of interest is bound. Also described is a pharmaceutical (e.g., vaccine) composition comprising an antigen-loaded immunogenic carrier complex. | 2016-05-19 |
20160136295 | BIOMARKERS FOR TREATMENT WITH ANTI-TUBULIN CHEMOTHERAPEUTIC COMPOUNDS - Provided herein are biomarkers for predicting sensitivity to treating cancer with anti-tubulin chemotherapeutic agents. | 2016-05-19 |
20160136296 | METHODS OF MAKING DLL3 ANTIBODY DRUG CONJUGATES - Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided. | 2016-05-19 |
20160136297 | TARGETING ABCB5 FOR CANCER THERAPY - The invention relates to methods for treating a subject by manipulating ABCB5 on a cell as well as related products. The methods include methods of treating cancer using ABCB5 binding molecules such as antibodies and fragments thereof. | 2016-05-19 |
20160136298 | METHOD OF PRODUCING AN IMMUNOLIGAND/PAYLOAD CONJUGATE - A method of producing an immunoligand/payload conjugate can encompass conjugating a payload to an immunoligand by means of a sequence-specific transpeptidase, or a catalytic domain thereof. | 2016-05-19 |
20160136299 | GLYCOENGINEERED ANTIBODY DRUG CONJUGATES - The current disclosure provides binding polypeptides (e.g., antibodies), and targeting moiety conjugates thereof, comprising a site-specifically engineered glycan linkage within native or engineered glycans of the binding polypeptide. The current disclosure also provides nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided. | 2016-05-19 |
20160136300 | ANTIBODY-DRUG CONJUGATE HAVING IMPROVED STABILITY AND USE THEREOF - The present invention relates to an antibody-drug conjugate comprising a drug conjugated to an antibody, a preparation method thereof and the use thereof. | 2016-05-19 |
20160136301 | PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS - The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention. | 2016-05-19 |
20160136302 | POLYETHYLENE GLYCOL BASED OLIGOMERS FOR COATING NANOPARTICLES, NANOPARTICLES COATED THEREWITH, AND RELATED METHODS - In a composition aspect of the invention, a nanoparticle coating comprises repeating polyacrylic acid monomers covalently bound together in an aliphatic chain having a plurality of carboxylic acid functional groups and modified carboxylic acid functional groups extending therefrom. A first portion of the modified carboxylic acid functional groups are modified by a PEG oligomer having a terminal methoxy functional group and a second portion of the modified carboxylic acid functional groups are modified by a PEG oligomer having at least one terminal sulfur moiety. | 2016-05-19 |
20160136303 | COMPOSITIONS AND METHODS FOR USE IN MEDICAL DIAGNOSIS - The present invention relates to compositions and methods for use in medical diagnosis and patient's monitoring. It more particularly relates to a biocompatible gel comprising nanoparticles and/or nanoparticle aggregates, wherein i) the nanoparticle and/or nanoparticles of the aggregate comprise an inorganic material comprising at least one metal element having an atomic number Z of at least 25, each of said nanoparticle and of said nanoparticle aggregate being covered with a biocompatible coating; ii) the nanoparticles and/or nanoparticle aggregate concentration is of about or less than 0.5% (w/w); and iii) the apparent viscosity at 2 s | 2016-05-19 |
20160136304 | COMPOSITIONS AND METHODS FOR USE IN ONCOLOGY - The present invention relates to compositions and methods for use in medical diagnostic and patient monitoring, typically in the context of therapy, in particular in the context of oncology to optimize tumor bed local irradiation. It more particularly relates to a biocompatible gel comprising nanoparticle and/or nanoparticles aggregates, wherein i) the density of each nanoparticle and of each nanoparticle aggregate is of at least 7 g/cm | 2016-05-19 |
20160136305 | COBALT-BASED MRI CONTRAST AGENT AND IMAGING SYSTEM - Novel, non-toxic cobalt-based contrast and imaging agents for use in enhanced medical imaging modalities and processes are described, as well the manufacture of markers containing such contrast agents is described, and uses for such imaging markers and contrast agents in a variety of therapeutic applications and devices. | 2016-05-19 |
20160136306 | SYSTEMS AND METHODS OF DETECTING INTERSTITIAL CYSTITIS - The invention provides systems and methods for providing a diagnostic examination to a patient, including, but not limited to a determination of the permeability of a patients' body cavity. | 2016-05-19 |
20160136307 | NANOPARTICLES FOR MAGNETIC PARTICLE IMAGING APPLICATIONS - One method of preparing a nanoparticle can include decomposing a compound at a high temperature, adding an acid to the solvent to form a reaction mixture, increasing the temperature of the reaction mixture to boiling point of the reaction mixture, and heating the reaction mixture at the boiling point for 60 to 120 minutes to produce the nanoparticle. The coated nanoparticle or the nanoparticle can be used in magnetic particles imaging. | 2016-05-19 |
20160136308 | METHODS AND APPARATUSES FOR THE LOCALIZATION AND TREATMENT OF DISEASE SUCH AS CANCER - Embodiments of the present invention provide methods of detecting disease, methods of treating disease using targeted hyperthermia, methods of treating disease using targeted chemical agents, methods of treating disease comprising accurate measurements of the efficacy of treatments. The effect of nanoparticles on magnetic fields can be used to determine the location of a disease, and a measure of the number of cells characteristic of the disease. This location and measure can be used to guide therapy, and provide information regarding the most effective therapy to be applied. The same nanoparticles can be used to facilitate hyperthermia treatments, and to allow targeted application of chemical therapeutic agents. | 2016-05-19 |
20160136309 | BIFUNCTIONAL CHELATING AGENTS BASED ON THE 1,4-DIAZEPINE SCAFFOLD (DAZA) FOR NON-INVASIVE MOLECULAR IMAGING - A compound fur radio metal complexation includes a chelator and one or more biological targeting vectors TV conjugated to said chelator, wherein the chelator has structure (A) or (B)or (C). | 2016-05-19 |
20160136310 | SYSTEMS, COMPOSITIONS, AND METHODS FOR LOCAL IMAGING AND TREATMENT OF PAIN - Pain factors are labeled with targeted agents or markers delivered into the body. The labeled pain factors are imaged with appropriate imaging tools in a manner allowing selective identification and localization of areas of pain source or transmission. The labeled pain factors allow spatial differentiation in the imaging sufficient to specify the location of the pain so as to drive therapeutic decisions and techniques in order to treat the pain. Pain factors labeled and imaged in this manner may include one or more of nerve factors, blood vessel factors, cellular factors, and inflammation factors. Labeled markers may include for example radioactive materials (e.g. tritiated or iodinated molecules) or other materials such as metal (e.g. gold) nanoparticles. Intermediary binding materials may be used, such as for example bi-specific antibodies. Therapeutic components of the system and method include for example localized energy delivery or ablation treatments, or local drug or other chemical delivery. Locations containing pain factor selectively bound by targeted agents are selectively treated with directed energy into a region containing the targeted agent bound to the pain factor. | 2016-05-19 |
20160136311 | ANTI-BACTERIAL LIGHT DELIVERY SYSTEM AND METHOD FOR DISINFECTING A SURFACE - A light delivery system and method are provided to promote a photochemical reaction for disinfecting a surface. The system includes a light source and a light diffusing element operatively coupled to the light source and further embedded within a surface to be disinfected. The light diffusing element outputs light to the surface to promote a photochemical reaction to disinfect the surface. A low scatter light transmission medium may further be coupled between the light source and the light diffusing element to transmit light from the light source remotely to the light diffusing element. | 2016-05-19 |
20160136312 | MULTIFUNCTION LIGHT-EMITTING DIODE LIGHTING APPARATUS - The multifunction LED lighting apparatus of the present invention includes a least one lighting LED, at least one ultraviolet (UV) LED, a substrate configured to have the at least one lighting LED and the at least one UV LED mounted thereon, and a cover disposed to face the substrate at a specific interval and configured to cover the lighting LED and the UV LED. The at least one lighting LED and the at least one UV LED are integrally mounted on the substrate and configured to form a single module of a thin sheet form, and the cover is installed to cover and support the single module placed on the inside wall of an application. | 2016-05-19 |
20160136313 | SYSTEMS AND METHODS FOR DISINFECTING A REMOTE CONTROL USING ULTRAVIOLET LIGHT - A remote control having an ultraviolet light emitting device for disinfecting the outer surfaces of the remote control is disclosed. In particular, the remote control may include an ultraviolet transmissive housing and internal ultraviolet emitting light emitting diodes. The ultraviolet transmissive housing allows the light from the internally mounted ultraviolet emitters to pass through the remote control's housing and kill bacteria, viruses, and other micro-organisms on the outer surface of the remote control by employing methods to automate safe and effective operations of ultraviolet light. | 2016-05-19 |
20160136314 | SANITIZING SURFACES - Sanitizing surfaces in a location related to aircraft. There are multiple rows of seats. A sanitization device includes a mobile body configured to travel along the aisle of the aircraft. An arm extends from the sanitization device laterally from the mobile body across the seats, and a source of UV radiation mounted on the sanitization device is directed across the seats exposing surfaces in the passenger area to UV radiation. There can be a unit hand operated, pushed down the aisle by hand, wings deployed and stowed by hand. There can be a plug in version with long extension cords that a human can keep from tangling. The operator can be protected with skin and eye protective gear and there can be remote control by an operator standing nearby. | 2016-05-19 |
20160136315 | EQUIPMENT FOR SANITIZING THE AIR CONDITIONING SYSTEM OF VEHICLES BY MEANS OF RADIANT CATALYTIC IONIZATION - An object of this certificate of addition includes the compaction of the equipment into two modules ( | 2016-05-19 |
20160136316 | METHOD FOR DELIVERING A VOLATILE MATERIAL - A method of delivering a volatile material to the atmosphere in a continuous manner is disclosed. The method includes providing a delivery engine having a reservoir that includes a volatile material mixture. The volatile material mixture includes about 40% to about 100%, by total weight, of the volatile materials each having a vapor pressure at 25° C. of less than about 0.1 torr. The delivery system also includes a microporous membrane enclosing the reservoir, wherein the microporous membrane comprises an average pore size of about 0.01 to about 0.03 microns. | 2016-05-19 |
20160136317 | Scent Devices and Methods - Scent devices and methods are provided. In one embodiment, the present invention can be a device to scent an environment comprising a scent and a structural component. The scent stick can have a length to average cross-sectional diameter ratio of at least about 4:1 according to some embodiments. The scent stick can be colored to blend into an environmental setting to make the presence of the scent stick unobtrusive. The scent stick may also be attached or hung by the addition of a hanger or hoop. The scent stick may be hung from a tree, automobile mirror or a person as an adornment. Other embodiments are also described. | 2016-05-19 |
20160136318 | Scent Devices and Methods - Scent devices and methods are provided. In one embodiment, the present invention can be a device to scent an environment comprising a scent and a structural component. The scent stick can have a length to average cross-sectional diameter ratio of at least about 4:1 according to some embodiments. The scent stick can be colored to blend into an environmental setting to make the presence of the scent stick unobtrusive. The scent stick may also be attached or hung by the addition of a hanger or hoop. The scent stick may be hung from a tree, automobile mirror or a person as an adornment. Other embodiments are also described. | 2016-05-19 |
20160136319 | VOLATILE MATERIAL DISPENSER - A dispenser includes a base holding a cartridge that includes a volatile material reservoir. The base includes a plurality of ribs that support a peripheral flange of the cartridge. The plurality of ribs support a portion of the peripheral flange having a permeable membrane disposed thereon. A first removable cover is attached to the base and has at least one aperture and a first regulating plate. The first cover may be removed and replaced by at least a second cover that has at least one aperture and a second, different regulating plate. | 2016-05-19 |
20160136320 | LENS CARE PRODUCT FOR OZONE-BASED CLEANING/DISINFECTING OF CONTACT LENSES - The present invention provides an aqueous lens care solution for disinfecting and/or cleaning contact lenses in an ozone-based lens care system. The lens care solution of the invention is a hypotonic solution, has an osmolality at about 25° C. of from about 200 mOsm/kg to about 260 mOsm/kg, and comprises at least one relatively-ozone-inert buffering agent selected from the group consisting of boric acid, sodium tetraborate, potassium tetraborate, acetic acid, sodium acetate, potassium acetate, and a mixture thereof. The aqueous lens care solution is compatible with ozone electrolytically generated in an ozone-based lens care system as characterized by comprising about 30 mM or less of chloride ion and less than about 10 mM of one or more ozone-interfering buffering agents. | 2016-05-19 |
20160136321 | SYNTHETIC SURFACTANT-FREE FINISH, SHEET HAVING SYNTHETIC SURFACTANT-FREE FINISH, ARTICLES HAVING SHEET WITH SYNTHETIC SURFACTANT-FREE FINISH, AND RELATED METHODS - Nonwoven (and film) topsheet and acquisition/distribution materials treated with a hydrophilic, synthetic surfactant-free finish, absorbent articles for infant or incontinence care that contain these materials, and methods for apply such finishes and/or making such absorbent articles. | 2016-05-19 |
20160136322 | GELATIN SPONGE COMPRISING AN ACTIVE INGREDIENT, ITS PREPARATION AND USE - The present invention is directed to a method for manufacturing a cross-linked gelatin sponge having a surface by providing a cross-linked gelatin sponge, wetting the surface of the sponge by applying a sufficient amount of liquid comprising a protein or peptide active ingredient, wherein a sufficient amount of liquid is one that retains the flexibility of the sponge even after drying. The sponge is then dried the sponge to obtain a flexible, dry and ready to use cross linked gelatin sponge having a layer of protein or peptide active ingredient on the surface thereof. | 2016-05-19 |
20160136323 | ANTIMICROBIAL HYDROCOLLOID DRESSING CONTAINING SEQUESTERED PEROXIDE AND PREPARATION THEREOF - This disclosure provides for an antimicrobial pressure sensitive adhesive composition that includes a sequestered peroxide source and devices that incorporate such a composition. | 2016-05-19 |
20160136324 | BIOLOGICAL FILM-FORMING AGENT FOR FACILITATION OF WOUND HEALING AND COATING AND PROTECTION OF BIOLOGICAL ORGANS - The present invention relates to a biological film-forming agent which is for facilitating wound healing and coating and protecting biological organs, and for coating and protecting damaged cells, wound surfaces, organs and damaged sites of organs, and wound surfaces reaching soft tissues such as muscle and facia, periosteum or bone cortex. Provided is a biological film-forming agent for suppressing exudation of intracellular fluid from damaged cells, suppressing expansion of inflammation reactions and secondary inflammation reactions resulting from production of fibrin and eliminating adverse effects caused by formation of stabilised fibrin on healing. Various problems can be solved by using the agent containing aluminium chloride, cyclodextrin and water as base components. | 2016-05-19 |
20160136325 | MOLDABLE BONE GRAFT COMPOSITIONS - The present disclosure relates to compositions useful in synthetic bone graft applications. Particularly, the disclosure teaches moldable bone graft compositions, methods of making said compositions, and methods of utilizing the same. | 2016-05-19 |
20160136326 | COMPOSITIONS AND METHODS FOR MAKING BIODEGRADABLE STRUCTURES - A composition including PPF or a PPF copolymer that can be used to fabricate biodegradable structures. The composition can be used in 3-D patterning (e.g., 3-D printing and sterolighography) methods. For example, 3-D patternable compositions include PPF or a PPF copolymer, a photoinitiator or photoinitiators, and a resolution control inhibitor or inhibitors. The compositions can be used to make biodegradable structures (such as cardivascular scaffolds). The biodegradable structures can be surface functionalized. The biodegradable structures can be used in methods of blood delivery in an individual. | 2016-05-19 |
20160136327 | 3D TISSUE-ENGINEERED BONE MARROW FOR PERSONALIZED THERAPY AND DRUG DEVELOPMENT - A tissue-engineered bone marrow for personalized therapy of a patient is described. The tissue-engineered bone marrow includes an autologous fibrin scaffold and a plurality of patient-derived cells isolated from the patient's bone marrow. The autologous fibrin scaffold is made using fibrinogen isolated from the patient's bone marrow. The plurality of patient-derived cells may include cells associated with a hematological or metastatic malignancy, bone marrow stromal cells, and endothelial cells. The patient-derived cells are cultured on the autologous fibrin scaffold to create the tissue-engineered bone marrow. The tissue-engineered bone marrow may be used for personalized drug screening. | 2016-05-19 |
20160136328 | FENESTRATION KITS FOR MAKING FENESTRATED PLACENTAL TISSUE ALLOGRAFTS AND METHODS OF USING THE SAME - Described herein are fenestrated placental tissue allografts, methods for using the same for treating wounds that produce an exudate and to promote the healing process, and apparatus and kits for making the same that minimize or eliminate cross-contamination with placental tissue from other placental donors. | 2016-05-19 |
20160136329 | SHAPED BONE GRAFT MATERIALS AND METHODS OF USE - A bone material comprising a coherent mass of cartridge milled and demineralized bone fibers is provided, the coherent mass having no binder disposed in or on the coherent mass. In some embodiments, a bone material comprising a lyophilized coherent mass of cartridge milled and demineralized bone fibers is provided, the lyophilized coherent mass having no binder disposed in or on the coherent mass. In some embodiments, a method of making an implantable bone material is provided, the method comprising drying a coherent mass of cartridge milled and demineralized bone fibers, the coherent mass having no binder disposed in or on the coherent mass. | 2016-05-19 |
20160136330 | Three-Dimensional Scaffold Functionalized with Micro-Tissues for Tissue Regeneration - The present invention concerns a biomaterial devoid of a growth factor, comprising: —a three-dimensional scaffold made of a biocompatible polymer; and—living cells, wherein said living cells are in form of microtissues and the nanofibrous three-dimensional scaffold is a nanofibrous scaffold. It further concerns a method for manufacturing such a biomaterial. Finally, it concerns such a biomaterial for use in the treatment of a bone and/or cartilage defect. | 2016-05-19 |
20160136331 | New Use of Dextran Sulfate - A graft composition intended for transplantation into a human patient comprises an injection solution comprising an isolated therapeutic cell transplant, wherein the therapeutic cell transplant is therapeutic to a human patient, and dextran sulfate, or a pharmaceutically acceptable salt thereof, having an average molecular weight of less than 20,000 Da. | 2016-05-19 |
20160136332 | THREE-DIMENSIONAL POROUS STRUCTURE MADE OF NANOFIBRE WEB FRAGMENTS AND METHODS FOR PRODUCTION THEREOF - A three-dimensional, porous structure made of fragments of a nanofibre web is provided. Furthermore, a method for the production of a three-dimensional, porous structure made of nanofibre web fragments is proposed. The three-dimensional, porous structure is used for example in medicine, preferably in regenerative medicine. Furthermore, the structure according to the invention made of fragments of a nanofibre web can be used for the treatment of tissue damage, for the immobilisation of biological cells, for the construction of biological tissue and as a biological filler in vitro and also in vivo. | 2016-05-19 |
20160136333 | DEVICE AND METHOD FOR COMPRESSING A HYDROGEL - The invention relates to a device and a method for compressing a hydrogel layer (H), wherein a separate piston ( | 2016-05-19 |
20160136334 | STENTS MODIFIED WITH MATERIAL COMPRISING AMNION TISSUE AND CORRESPONDING PROCESSES - A stent scaffold combined with amniotic tissue provides for a biocompatible stent that has improved biocompatibility and hemocompatibility. The amnion tissue can be variously modified or unmodified form of amnion tissue such as non-cryo amnion tissue, solubilized amnion tissue, amnion tissue fabric, chemically modified amnion tissue, amnion tissue treated with radiation, amnion tissue treated with heat, or a combination thereof. Materials such as polymer, placental tissue, pericardium tissue, small intestine submucosa can be used in combination with the amnion tissue. The amnion tissue can be attached to the inside, the outside, both inside and outside, or complete encapsulation of the stent scaffold. In some embodiments, at least part of the covering or lining comprises a plurality of layers of amnion tissue. The method of making the biocompatible stent and its delivery and deployment are also discussed. | 2016-05-19 |
20160136335 | ENHANCEMENT OF ANTIMICROBIAL SILVER, SILVER COATINGS, OR SILVER PLATINGS - Antimicrobial metal ion coatings. In particular, described herein are coatings including an anodic metal (e.g., silver and/or zinc and/or copper) that is co-deposited with a cathodic metal (e.g., palladium, platinum, gold, molybdenum, titanium, iridium, osmium, niobium or rhenium) on a substrate (including, but not limited to absorbable/resorbable substrates) so that the anodic metal is galvanically released as antimicrobial ions when the apparatus is exposed to a bodily fluid. The anodic metal may be at least about 25 percent by volume of the coating, resulting in a network of anodic metal with less than 20% of the anodic metal in the coating fully encapsulated by cathodic metal. | 2016-05-19 |
20160136336 | Process for the Production of Storable Implants with an Ultrahydrophilic Surface - The present invention concerns a process for the production of implants with an ultrahydrophilic surface as well as the implants produced in that way and also processes for the production of loaded, so-called bioactive implant surfaces of metallic or ceramic materials, which are used for implants such as artificial bones, joints, dental implants or also very small implants, for example what are referred to as stents, as well as implants which are further produced in accordance with the processes and which as so-called “delivery devices” allow controlled liberation, for example by way of dissociation, of the bioactive molecules from the implant materials. | 2016-05-19 |
20160136337 | PROGENITOR ENDOTHELIAL CELL CAPTURING WITH A DRUG ELUTING IMPLANTABLE MEDICAL DEVICE - A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is coated with a pharmaceutical composition consisting of a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis. | 2016-05-19 |
20160136338 | AUTOMATIC EXCREMENT PROCESSING DEVICE - The present invention relates to an automatic excrement processing device comprising: a cup unit ( | 2016-05-19 |
20160136339 | SYSTEMS AND METHODS FOR APPLYING REDUCED PRESSURE THERAPY - Embodiments of reduced pressure systems and methods for operating the systems are disclosed. In some embodiments, a system can include a source of negative pressure and a controller configured to present GUI screens for controlling and monitoring operation of the system. The controller can be configured to receive, via the GUI, an adjustment of a negative pressure therapy parameter and adjust (or cause adjustment) of the operation of the negative pressure source based on received adjustment. The controller can be further configured to record historical data parameters associated with negative pressure therapy parameters. The controller can also be configured to transmit (or cause transmission) over a communication channel at least some of recorded historical data. The system can be configured to provide external connectivity for accomplishing various activities, such as location tracking, compliance monitoring, tracking of operational data, remote selection and adjustment of therapy settings, etc. | 2016-05-19 |
20160136340 | TEMPERATURE-ADJUSTED HEATER FOR TRANSFUSION - A temperature-adjusted heater for transfusion includes a clamping member and a temperature-controlled unit. The clamping member defines a through hole, for a transfusion tube pass through and fixed therein. The temperature-controlled unit connecting to power supply, includes a heating member, an adjusting current circuit, and an adjusting button. The heating member is mounted in the clamping member, in communication with the through hole, and firmly against the transfusion tube. The heating member and the adjusting button are in series with the adjusting current circuit, and the adjusting button is operated to change the resistance value of the adjusting current circuit. | 2016-05-19 |
20160136341 | CATHETER DEVICE - The catheter device comprises a motor at the proximal end of the catheter device and a drive shaft, extending from the proximal end section to the distal end section of the catheter device, for driving a rotating element located at the distal end of the catheter device. The catheter device also comprises a hose-like catheter body which encompasses the drive shaft and extends from the proximal end section to the distal end section. At the proximal end of the catheter device, the drive shaft is connected to a motor by a clutch. The clutch is a magnetic clutch with a proximal and a distal magnet unit. The proximal magnet unit is connected to the motor and the distal magnet unit to the drive shaft. The distal magnet unit is mounted fluid-tight in a clutch housing. The proximal end of the catheter body makes a fluid-tight connection with the clutch housing. | 2016-05-19 |
20160136342 | CATHETER DEVICE - The catheter device comprises a motor at the proximal end of the catheter device and a drive shaft, extending from the proximal end section to the distal end section of the catheter device, for driving a rotating element located at the distal end of the catheter device. The catheter device also comprises a hose-like catheter body which encompasses the drive shaft and extends from the proximal end section to the distal end section. At the proximal end of the catheter device, the drive shaft is connected to a motor by a clutch. The clutch is a magnetic clutch with a proximal and a distal magnet unit. The proximal magnet unit is connected to the motor and the distal magnet unit to the drive shaft. The distal magnet unit is mounted fluid-tight in a clutch housing. The proximal end of the catheter body makes a fluid-tight connection with the clutch housing. | 2016-05-19 |
20160136343 | INTRA-AORTIC BALLOON APPARATUS, ASSIST DEVICES AND METHODS FOR IMPROVING FLOW, COUNTERPULSATION AND HAEMODYNAMICS - A circulatory assist apparatus comprising: an inflatable pumping balloon having a proximal end joined to an elongated balloon catheter, the balloon catheter having a distal end joined to the pumping balloon and a proximal end, separated from the distal end by a length sufficient to extend from within a circulatory lumen to the outside of a patient's body, for receiving positive and negative pressure pulses from a pump to inflate and deflate the pumping balloon; and a radially expandable frame, mounted on one of a segment extending distally from the pumping balloon, the balloon catheter, and a sleeve tube surrounding the balloon catheter. The expandable frame is manipulate to expand within the circulatory lumen, and functions to space apart the inflatable balloon from the circulatory lumen, having a first diameter in a collapsed configuration for intraluminal delivery and a second, larger diameter in an expanded configuration achieved by said manipulation. | 2016-05-19 |
20160136344 | VENTRICULAR ASSIST DEVICE AND METHOD - A ventricular assist device includes a stent for placement within a cardiac artery and arranged for placement, the stent arranged to have an open configuration defining a flow path, a rotor sized to fit within the stent and arranged for percutaneous placement the flow path, the rotor including a surface disposed about a central portion and angled with respect to the flow path and having a first plurality of magnets. A collar is sized for placement about the cardiac artery and includes a stator. A power source is coupled to the stator, and the stator and the rotor are arranged to rotate the rotor about an axis. A timing control module controls a rotational speed of the rotor. Accordingly, the surface of the rotor is arranged to move blood along the flow path in response to rotation of the rotor. | 2016-05-19 |
20160136345 | DIALYSIS SYSTEM HAVING AN AUTOCONNECTION MECHANISM - A dialysis system including a disposable fluid pumping cassette including at least one flexible membrane attached to a housing and at least one port extending from the housing, the at least one port including a spike; at least one dialysis fluid supply in fluid communication with at least one tubing and tubing connector; an autoconnection device including a shuttle for moving the at least one tubing and tubing connector towards the spike of the at least one port, the autoconnection device including at least one lead screw in mechanical communication with the shuttle, a motor and power transmission equipment to transmit power from the motor to the at least one lead screw; and a controller programmed to operate the motor to move the at least one tubing and tubing connector towards the spike of the at least one port of the disposable fluid pumping cassette. | 2016-05-19 |
20160136346 | HEMODIALYSIS APPARATUS - Provided is a hemodialysis apparatus including a hemodialyzer in which mass transfer occurs between blood and dialysate, a blood tube connecting the hemodialyzer and a patient to allow blood to flow therethrough, a blood flow controller which controls the blood flow passage through the blood tube, a dialysate supply pump supplying dialysate to the hemodialyzer, and a dialysate discharge pump discharging dialysate having passed through the hemodialyzer. The dialysate supply pump and the dialysate discharge pump further include a tube pressurizing member and a one-way valve or a roller and a roller driver. The blood tube includes a first blood tube in which blood of a patient is supplied to the hemodialyzer and a second blood tube in which blood passing through the hemodialyzer is returned to the patient. | 2016-05-19 |
20160136347 | AMBULATORY LUNG ASSIST DEVICE WITH IMPLANTED BLOOD PUMP AND OXYGENATOR - The present disclosure provides a system for oxygenating blood. The system may include an implantable blood pump that may draw a supply of blood from the circulatory system of a mammalian subject, such as a human being. The blood pump may provide the supply of blood to an adaptor, where the supply of blood may be supplied to either or both of a first branch or second branch. The first branch may lead to an external blood oxygenator. The oxygenator may oxygenate the blood, and the blood may be returned to the circulatory system of the mammalian subject. The second branch may bypass the oxygenator and may connect to the circulatory system of the mammalian subject. In this regard, while the blood is supplied to the second branch, the oxygenator may be disconnected and blood may be prevented from entering the first branch. | 2016-05-19 |
20160136348 | METHOD AND DEVICE FOR SEPARATING BLOOD USING A CENTRIFUGE - The invention relates to a method and a device for separating blood using a centrifuge in order to obtain different blood fractions. A separation container may be filled with blood via a feed connection that can be aseptically connected to the container, the relevant blood fraction may be removed from the separation container via a removal connection that can be aseptically connected to the container and both the feed device and the removal device folln a respective closed system during the sterile connection to the separation container. The separation container may have at least one feed connection that can be aseptically connected to the container and at least one removal connection that can be aseptically connected to the container, to which hermetically sealed feed and removal devices can be aseptically attached in a sterile manner. | 2016-05-19 |
20160136349 | IRRIGATOR FOR WASHING WHILE SURGERY OPERATION - A surgical irrigator is disclosed. The surgical irrigator includes a body unit including an engagement module, a spray unit engaged with the body unit, and a control module mounted to the body unit and configured to control an amount of a cleansing solution sprayed through the spray unit. The engagement module includes a ring-type body, and an engagement unit formed on an inner circumferential surface of the body and configured to fix the spray unit in engagement with the spray unit. | 2016-05-19 |
20160136350 | IRRIGATOR FOR WASHING WHILE SURGERY OPERATION - A surgical irrigator is disclosed. The surgical irrigator includes a body unit including an engagement module, and a spray unit engaged with the body unit. The engagement module includes a ring-type body, and an engagement unit formed on an inner circumferential surface of the body and configured to fix the spray unit in engagement with the spray unit. | 2016-05-19 |
20160136351 | IRRIGATOR FOR WASHING WHILE SURGERY OPERATION - A surgical irrigator is disclosed. The surgical irrigator includes a body unit, a spray unit engaged with one end of the body unit, and a control module mounted to the body unit and configured to control an amount of a cleansing solution sprayed through the spray unit. The control module includes a body part having a through hole configured to allow the cleansing solution to pass therethrough, and a driving part disposed inside the body part and configured to control an opening degree of the through hole. | 2016-05-19 |
20160136352 | MEDICAL ORGANIZING EQUIPMENT - An organizational system is disclosed, which comprises syringe compartments and vial compartments. Each of the vial compartments corresponds to one of the syringe compartments. The syringe compartments and vial compartments are designed to hold syringes and vials in an organized manner. | 2016-05-19 |
20160136353 | COMBINATION LINEAR POTENTIOMETER AND SYRINGE THUMBPRESS DETECTION SENSOR AND RELATED SYSTEMS AND METHODS - A combined detectional and positional sensor for a syringe pump. The sensor can comprise a syringe thumbpress clamp that is pivotable so that an engagement pin deflects a linear membrane potentiometer first circuit thus providing a closed switch for detection of a syringe in the pump and a variable signal return for indication of plunger head position. Embodiments of the sensor can be used in relatively large syringe pumps and in relatively small syringe pumps, for example. | 2016-05-19 |
20160136354 | Multifunction Capacitive Sensor for Medical Pump - A medical pump or the like provides for a multi-function flow monitor that provides for capacitive plates positioned on opposite sides of the IV line to sense changes in the electrical environment within the IV line to deduce IV line pressure, the presence of IV fluid bubbles, the presence of the IV line within the pump, and/or correct pump operation. Each of these conditions may he determined by different analysis of the capacitance across the capacitive plates. | 2016-05-19 |
20160136355 | MEDICAL INFUSION PUMP MECHANISM - A medical device pump with a housing with a compartment for removably receiving a cartridge containing a therapeutic agent, a conduit configured to operatively provide a fluid flow path for therapeutic agent to exit from the cartridge, a user activated delivery button, a trigger mechanism, and a pump mechanism employing an articulating, coiled drive spring. | 2016-05-19 |
20160136356 | CATHETER MONITOR INTEGRATION WITH PATIENT SUPPORT, HYGIENE AND HEALTHCARE COMMUNICATION SYSTEMS - Catheter monitor integration with patient support systems, such as patient beds, and with other healthcare communication systems including hand hygiene systems is provided. A patient bed that transmits bed data and catheter monitor data is disclosed. When catheter tubing is connected to a catheter monitor integrated into a patient bed, the bed automatically implements a falls prevention protocol. A countdown timer pertaining to removal of catheter tubing from a patient is displayed on one or more display devices. Monitoring for caregiver handwashing compliance in connection with use of a catheter monitor or a catheter kit is also provided. | 2016-05-19 |
20160136357 | SINGLE NEEDLE INTEGRATED ARTIFICIAL PANCREAS - Disclosed is a single needle integrated artificial pancreas, wherein the single needle integrated artificial pancreas comprises a fluid reservoir unit; a fluid driving unit connected to the drug reservoir unit; an indwelling unit connected to the fluid reservoir unit and comprising a glucose sensor, an insulin indwelling cannula, a puncture needle and an inserter; wherein the glucose sensor and the indwelling cannula are simultaneously implanted in the same subcutaneous tissue in a patient via the inserter under the aid of the puncture needle; and the puncture needle is a steel puncture needle or groove puncture needle; and a glucose monitoring and insulin delivery control unit is respectively connected to the fluid reservoir unit, the fluid driving unit and the indwelling unit. The single needle integrated artificial pancreas reduces the chance of a diabetic patient being infected and is simple in installation and convenient to use. | 2016-05-19 |
20160136358 | DRUG DELIVERY DEVICE - The invention relates to a drug delivery device for selecting and dispensing a number of user variable doses of a medicament including a dose limiter for preventing the setting of a dose, which exceeds the amount of liquid left in a cartridge of the drug delivery device. The device comprises a cartridge ( | 2016-05-19 |
20160136359 | Retracting Sheath Detachable Safety Needle with Moving Spring - A passive safety needle device is disclosed having a housing, a needle hub, a needle cannula, a retractable sheath, a spring to bias the retractable sheath in a distal direction to cover the distal end of the needle cannula, a radial protrusion to cause the spring to move from the proximal spring position to the distal spring position, and a catch to secure the distal end of the spring to the distal end of the housing. The spring may bias the retractable sheath in a distal direction to cover the distal end of the needle cannula. The radial protrusion causes the spring to move from a proximal spring position to the distal spring position towards the catch located at the distal end of the housing. | 2016-05-19 |
20160136360 | DEVICES FOR INJECTING A SUBSTANCE AND METHODS THEREFOR - A device for administering injections includes a housing having an upper end, a lower end including a bottom surface with an injection needle opening, and an axis extending between the upper and lower ends. The device includes a needle housing with an injection needle. The needle housing is disposed within the housing for moving between a retracted position and an extended position. The device has an injection actuator for commencing an injection cycle including a first stage in which the needle housing and said plunger base are coupled together and move in a first direction along the axis and a second stage in which the needle housing and the plunger base are decoupled from one another so that the plunger base is free to move away from the needle housing in a second direction that is opposite the first direction. | 2016-05-19 |
20160136361 | Reusable Syringe - The invention relates to a reusable syringe with a syringe body for receiving an ampoule. At the front end of the syringe body there is an opening which defines an axis along which a needle can be inserted. A plurality of holding segments are arranged around this axis and engage behind a needle carrier in the longitudinal direction. According to the invention, a holding segment designed as a thread part is movable in the radial direction. The invention further relates to a system composed of a reusable syringe, a needle carrier, and a container for used needles. Moreover, the invention includes an associated method for connecting and releasing a needle of a reusable syringe. The movable holding segment facilitates the release of the threaded connection of the needle carrier from the syringe body and makes the reusable syringe safer to use. | 2016-05-19 |
20160136362 | Venipuncture Assist Device - A venipuncture assist device includes a main body having a first surface configured to confront a target venipuncture site. The device further includes a vein capture channel disposed within the first surface configured to urge a portion of a patient's tissue and subcutaneous vein therein when the vein capture channel is evacuated by vacuum, wherein the urging creates a bend in the vein for piercing by a venipuncture needle. The device further includes one or more needle channels extending from a front main body surface configured to receive and guide the needle into the bend in the vein. | 2016-05-19 |
20160136363 | REPEATABLE INJECTION TARGETING SYSTEM - Systems and method of targeted injection are provided. A method includes: capturing an image of a subject; displaying the image on a touch screen display; providing input to the touch screen display, wherein the input generates at least one mark superimposed on the image; saving the image and the at least one mark as a modified image; projecting the modified image onto the subject; and administering an injection to the subject where the at least one mark is projected on the subject. | 2016-05-19 |
20160136364 | NITRIC OXIDE DELIVERY SYSTEM AND METHODS OF USE - Embodiments of the present disclosure provide systems and devices for delivering gaseous Nitrous Oxide (gNO) under therapeutic parameters to reduce infection in a subject. Certain embodiments include devices and systems for delivering pressurized gNO to reduce bioburden and promote healing in the wounds of subjects having various disease conditions, including skin and soft tissue infections (SSTIs) and osteomyelitis. In some embodiments, the present disclosure provides portable wound healing devices for delivering pressurized gNO to the site of a wound to treat various disease conditions in a subject. | 2016-05-19 |